Pharmaceutical

Donepezil

(RS)-2-[(1-Benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one

Evidence TierAWADA NOT PROHIBITED

tuneTypical Dose

5-10

watchEffect Window

12-24 weeks to establish baseline efficacy improvements.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Donepezil is a prescription acetylcholinesterase inhibitor used in Alzheimer’s disease. It is used to modestly improve cognitive symptoms and daily functioning by increasing cholinergic signaling.

Controlled trials show modest improvements or slower decline in cognition and activities of daily living in Alzheimer’s disease and some dementias. Benefits are symptomatic rather than disease modifying and vary by baseline severity. Minority studies examine mild cognitive impairment with inconsistent results. Side effects can limit tolerability, and outcomes depend on diagnosis and adherence.

Specific, reversible inhibitor of acetylcholinesterase (AChE) that enhances cholinergic transmission by preventing acetylcholine breakdown.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Modest improvement in cognitive function and daily living activities in Alzheimer's disease.

Secondary Outcomes

  • No significant benefit demonstrated for Mild Cognitive Impairment prevention or healthy adult enhancement.

Safety

Contraindications and Interactions

Contraindications

  • Sick sinus syndrome
  • AV block
  • Active peptic ulcer
  • Severe asthma/COPD

Side effects

  • Nausea
  • Diarrhea
  • Insomnia
  • Vivid dreams
  • Muscle cramps
  • Fatigue
  • Loss of appetite

Interactions

  • Anticholinergics
  • NSAIDs
  • Beta-blockers
  • Succinylcholine

Avoid if

  • Healthy adult seeking nootropic use
  • Sick sinus syndrome
  • Active peptic ulcer

Evidence

Study-level References

donepezil-SRC-001Meta-analysis of RCTs
Sourceopen_in_new

Birks JS, Harvey RJ. "Donepezil for dementia due to Alzheimer's disease." Cochrane Database Syst Rev. 2018.

Population: Alzheimer's patients

Key findings: Patients on donepezil experienced benefits in cognitive function, activities of daily living, and clinician's global assessment. The 10 mg/day dose provided marginally better cognitive outcomes than 5 mg/day but with more adverse events.

Paper content

Patients on donepezil experienced benefits in cognitive function, activities of daily living, and clinician's global assessment. The 10 mg/day dose provided marginally better cognitive outcomes than 5 mg/day but with more adverse events.

donepezil-SRC-002Cochrane systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_new

Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018;6(6):CD001190. doi:10.1002/14651858.CD001190.pub3. PMID:29923184.

Population: Patients with mild, moderate, or severe Alzheimer's disease dementia across 30 RCTs.

Dose protocol: Donepezil 5 mg, 10 mg, or 23 mg daily versus placebo across 30 RCTs (8,257 participants)

Key findings: Donepezil improved cognition and activities of daily living at 26 weeks. No benefit for behavioral symptoms or quality of life. Adverse events increased with dose.

Notes: Cochrane review. The definitive pooled evidence base for donepezil in Alzheimer's disease.

Paper content

This Cochrane review pooled 30 randomized controlled trials (8,257 participants) evaluating donepezil for Alzheimer's disease dementia. After 26 weeks, donepezil at 5 and 10 mg improved cognitive function and activities of daily living compared to placebo. There was no difference for behavioral symptoms or quality of life. Adverse events, particularly nausea, vomiting, and diarrhea, were more common with donepezil and increased with higher doses. The review confirmed that donepezil provides modest but real cognitive and functional benefits in Alzheimer's disease, while clearly distinguishing the domains where it does and does not help.

donepezil-SRC-003Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_new

Sheikh M, Ammar M. Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis. Front Neurosci. 2024;18:1398952. doi:10.3389/fnins.2024.1398952. PMID:39104606.

Population: Patients with dementia at any stage across 18 RCTs.

Dose protocol: Donepezil 5 mg and 10 mg daily versus placebo across 18 RCTs (5,948 participants)

Key findings: 10 mg dose significantly improved MMSE score. Both doses showed cognitive benefit, with 10 mg more efficacious.

Notes: Updated 2024 meta-analysis confirming the dose-response relationship.

Paper content

This 2024 systematic review and meta-analysis pooled 18 RCTs (5,948 participants) comparing donepezil 5 mg and 10 mg daily to placebo. The 10 mg dose significantly improved MMSE scores, and both doses showed cognitive benefit on standardized assessments. This provides updated pooled evidence confirming the dose-response relationship for donepezil in dementia, with the 10 mg dose offering greater efficacy but at a higher side-effect cost. The analysis supports the clinical practice of starting at 5 mg and considering uptitration based on tolerance.

Guides

Setup

Help